



The role of Neoadjuvant Radiotherapy in Pancreatic Cancer , current standards and future prospects

Dr. Oriol Pares

Radiation Oncologist, Portugal

In Pancreatic Cancer (PaCa), complete resection offers the only hope of cure, but the results achieved so far by surgery alone are suboptimal.

Neoadjuvant chemoradiotherapy (CRT) appears to be feasible in resectable early PaCa (EaPC) and locally advanced PaCa (LAPC) and provides an observation period to exclude from surgical resection those patients with rapidly progressive disease or with clinically occult micrometastases at diagnosis. In locally advanced tumors, neoadjuvant CRT provides the opportunity for downstaging and may allow patients to undergo resection. But stronger evidence from phase III randomized trials is needed both for EaPC and LAPC.